Skip to main content
Premium Trial:

Request an Annual Quote

Affy Shares Surge 12 Percent One Day After Firm Reported 20-Percent Q4 Revenue Growth

NEW YORK, Jan. 27 (GenomeWeb News) - Shares in Affymetrix were up 11.95 percent, or $4.34, at $40.67 in late-afternoon trading today, one day after the company reported substantial gains in revenue during the fourth quarter.


The Santa Clara, Calif.-based firm yesterday said fourth-quarter revenue grew more than 20 percent to $107.7 million from $89.2 million in the fourth quarter of 2003. The firm surpassed analysts' estimates for Q4 revenue of $103.8 million.


Revenue for the three months ended Dec. 31 included GeneChip receipts of $57.4 million, instrument revenue of $25.2 million, and reagent revenue of $9.6 million. Total product and product-related revenue for the quarter was $104.9 million compared to $85.3 million for the comparable period a year ago.


The microarray market leader also sharply increased its net earnings for the quarter. For the quarter, the firm posted net income of $27.1 million, or $.44 per basic share, compared to income of $16 million, or $.27 per basic share, year over year.


R&D spending in the period increased to $73.4 million from $65.9 million year over year.


Affymetrix is predicting fiscal 2005 revenue of $405 million and earnings per diluted share of $1.12. For the first quarter of 2005, the firm expects $90 million in total revenue.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.